Abstract

Innate cell engager (ICE®) constructs are bispecific tetravalent antibodies targeting specific tumor antigens and simultaneously engaging natural killer (NK) cell and macrophage receptors for the destruction of tumor cells. Pre-complexing of ICE® constructs with adoptive NK cells is a novel approach to enhance NK cell activity. The suitability of such complexes for cryopreservation, whilst retaining the biological activity and specificity, may enable the development of off-the-shelf NK cell products. This study investigates the binding affinity of ICE® constructs targeting EpCAM and NK cell receptors CD16A, NKG2D, or NKp46 to the corresponding antigens, the ICE® antitumor activity, and feasibility of cryopreservation. Cell surface retention assays using primary NK cells confirmed a substantially slower ICE® construct dissociation kinetics compared with control molecules, suggesting the formation of durable complexes independently of the CD16A polymorphism. The high-affinity NK cell and EpCAM/CD16A ICE® complexes were superior to those engaging NKG2D or NKp46 receptors when tested for the NK-cell-mediated elimination of EpCAM-expressing tumor cells. Moreover, the potency and efficacy of these complexes were unaffected after a single freeze–thaw cycle. CD16A-selective ICE® drug candidates complexed with NK cells hold promise as novel cryopreserved off-the-shelf NK cell products with chimeric antigen receptor-like NK cell properties, capable of effective depletion of tumor cells.

Highlights

  • Soluble recombinant antigen variants were constructed as fusion proteins comprising the extracellular domain (ECD) of EpCAM (Uniprot: P16422), NKG2D (Uniprot: P26718), NKp46 (Uniprot: O76036), CD16A (Uniprot: P08637, F → V: VAR_003960), CD16B (Uniprot: O75015), the monomeric human IgG1 Fc with the effector function silenced by the introduction of the L234F, L235E, and D265A mutations, and Avi-Tag [31]

  • The ICE® construct design was based on the tetravalent bispecific single-chain fragment variable fusion antibodies specific for the human CD16A Natural killer (NK) cell receptor and either the human EpCAM or CD30 antigen (Table S1)

  • A robust and effective methodology for pre-complexing of bispecific ICE® constructs with primary NK cells (CAR-like NK-cell products) and cryopreservation of such complexes for adoptive transfer without a loss of specificity and cytotoxicity could significantly advance the development of off-the-shelf NK cell products, thereby circumventing the drawbacks of personalized NK cell therapies for patients with cancer

Read more

Summary

Introduction

Natural killer (NK) cells and macrophages are critical components of the innate immune system acting in tumor immunosurveillance, leading to the destruction of transformed cells via the antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mechanisms, respectively [3,4]. Beyond the tumor immunosurveillance stage, NK cells and macrophages play a significant role in facilitating the elimination of tumor cells in cancers that have already progressed [3,4]. High levels of tumor-infiltrating NK cells associate with an improved prognosis in patients with some cancers, including those with breast, head and neck, squamous cell lung, and prostate cancer, and gastrointestinal stromal tumors, and neurofibroblastoma. In patients with hepatocellular carcinoma, a higher intratumoral density of NK cells correlates with longer overall survival and disease-free progression [5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call